News for Myriad Genetics, Inc. (MYGN)

SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., ( MYGN), a leader in molecular diagnostic testing and precision medicine, today annou

Myriad Genetics (MYGN) has introduced the early access phase of its innovative FirstGene Multiple Prenatal Screen. The company is initiating a comprehensive stu

Myriad Genetics (MYGN) has revealed interim outcomes from the MONSTAR-SCREEN 3 clinical study, conducted in collaboration with the National Cancer Center Hospit

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surge

Myriad Genetics, Inc.

Myriad Genetics (MYGN) highlights seven new research studies at the 2025 ASCO Annual Meeting. The MONSTAR-SCREEN-3 study shows 100% baseline detection o

On May 21, 2025, Myriad Genetics (MYGN) experienced a significant change in its stock market standing as Scotiabank analyst Sung Ji Nam downgraded the company's

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Scotiabank has adjusted its outlook on Myriad Genetics (MYGN), lowering its rating to Sector Perform from Outperform. Concurrently, the price target has been re

Scotiabank has adjusted its stance on Myriad Genetics (MYGN), moving the company's rating from Outperform to Sector Perform. The bank has also set a new price t

Myriad Genetics (MYGN) has seen its price target reduced by Morgan Stanley analyst Tejas Savant, who adjusted it from $16 down to $7. The decision to maintain a

U.S. stocks were lower, with the Nasdaq Composite falling around 50 points on Monday. Shares of CI&T Inc. CINT rose sharply during Monday's session. JP Morgan...

On May 15, 2025, Piper Sandler analyst Dave Weiner announced an update regarding Myriad Genetics (MYGN), a prominent player in the field of genetic testing and

Piper Sandler has revised its price target for Myriad Genetics (MYGN), reducing it from $12.50 to $9. This adjustment follows the latest quarterly performance o

**media[626275]**

We recently published a list of Billionaire Larry Robbins’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against other stock picks with huge upside potential. Larry Robbins is an American hedge fund manager and philanthropist who founded Glenview Capital Management in […]

Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (”œMyriad” or the ”œCompany”) (NASDAQ: [url="]MYGN[/url]) in

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Wednesday. The Dow traded up 0.64% to 41,090.68 while the NAS...

Raymond James has revised Myriad Genetics' (MYGN) price target from $19 down to $10 while maintaining an Outperform rating on the stock. The adjustment follows